cancers-logo

Journal Browser

Journal Browser

Announcements

6 November 2025
MDPI Launches the Michele Parrinello Award for Pioneering Contributions in Computational Physical Science


MDPI is delighted to announce the establishment of the Michele Parrinello Award. Named in honor of Professor Michele Parrinello, the award celebrates his exceptional contributions and his profound impact on the field of computational physical science research.

The award will be presented biennially to distinguished scientists who have made outstanding achievements and contributions in the field of computational physical science—spanning physics, chemistry, and materials science.


About Professor Michele Parrinello

"Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking what is going to happen to me and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”

——Professor Michele Parrinello

Born in Messina in 1945, he received his degree from the University of Bologna and is currently affiliated with the Italian Institute of Technology. Professor Parrinello is known for his many technical innovations in the field of atomistic simulations and for a wealth of interdisciplinary applications ranging from materials science to chemistry and biology. Together with Roberto Car, he introduced ab initio molecular dynamics, also known as the Car–Parrinello method, marking the beginning of a new era both in the area of electronic structure calculations and in molecular dynamics simulations. He is also known for the Parrinello–Rahman method, which allows crystalline phase transitions to be studied by molecular dynamics. More recently, he has introduced metadynamics for the study of rare events and the calculation of free energies.

For his work, he has been awarded many prizes and honorary degrees. He is a member of numerous academies and learned societies, including the German Berlin-Brandenburgische Akademie der Wissenschaften, the British Royal Society, and the Italian Accademia Nazionale dei Lincei, which is the major academy in his home country of Italy.


Award Committee

The award committee will be chaired by Professor Xin-Gao Gong, a computational condensed matter physicist, academician of the Chinese Academy of Sciences, and professor at the Department of Physics, Fudan University. Professor Xin-Gao Gong will lead a panel of several senior experts in the field to oversee the evaluation and selection process.

The Institute for Computational Physical Sciences at Fudan University (Shanghai, China), led by Professor Xin-Gao Gong, will serve as the supporting institute for the award.

"We hope the Michele Parrinello Award will recognize scientists who have made significant contributions to the field of computational condensed matter physics and at the same time set a benchmark for the younger generation, providing clear direction for their pursuit—this is precisely the original intention behind establishing the award."

——Professor Xin-Gao Gong

The first edition of the award was officially launched on 1 November 2025. Nominations will be accepted before the end of March 2026. For further details, please visit mparrinelloaward.org.


About the MDPI Sustainability Foundation and MDPI Awards

The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which is dedicated to advancing sustainable development through scientific progress and global collaboration. The foundation also oversees the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award. The establishment of the Michele Parrinello Award will further enrich the existing award portfolio, providing continued and diversified financial support to outstanding professionals across various fields. 

In addition to these foundation-level awards, MDPI journals also recognize outstanding contributions through a range of honors, including Best Paper Awards, Outstanding Reviewer Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, Editor of Distinction Awards, and others. These initiatives aim to recognize excellence across disciplines and career stages, contributing to the long-term vitality and sustainability of scientific research.

Find more information on awards here.

9 January 2026
Cervical Cancer Awareness Month


In January, the WHO-recognized Cervical Cancer Awareness Month features global activities to raise awareness and support for Cervical Cancer research. We would like to take this opportunity to extend our appreciation to all of the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of Cervical Cancer that have been published in MDPI’s Journal Cluster of Oncology: Cancers, Current Oncology, Onco and Targets. We hope this announcement will provide useful information for all individuals interested in this field.

Long-Term Outcomes of Co-Testing with 3-Type HPV mRNA (16/18/45) and Cytology in Women Under 40: A Real-World Cohort from Northern Norway (8–10 Years of Follow-Up)
by Marie Bostrøm, Gunnar Skov Simonsen and Sveinung Wergeland Sørbye
Targets 2025, 3(4), 36; https://doi.org/10.3390/targets3040036

The Role of Tissue Factor-Positive Microparticles in Gynecological Cancer-Associated Disseminated Intravascular Coagulation: Molecular Mechanisms and Clinical Implications
by Muqaddas Qureshi, Muhammad Tanveer Alam and Ahsanullah Unar
Onco 2025, 5(3), 33; https://doi.org/10.3390/onco5030033

The Neutrophil-to-Lymphocyte Ratio (NLR) as a Potential Predictor in Conization Outcomes for Cervical Cancer
by Balázs Vida, Emese Keszthelyi, Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Balázs Lintner, Ferenc Bánhidy, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth and Márton Keszthelyi
Cancers 2025, 17(11), 1856; https://doi.org/10.3390/cancers17111856

A Systematic Review of SBRT Boost for Cervical Cancer Patients Who Cannot Benefit from Brachytherapy
by Iozsef Gazsi and Loredana G. Marcu
Curr. Oncol. 2025, 32(3), 170; https://doi.org/10.3390/curroncol32030170

Neutrophil/Lymphocyte Ratio (NLR) as a Predictive Marker for p16 Positivity and Cervical Cancer Progression: Insights from the SCOPE Study
by Zsófia Tóth, Lotti Lőczi, Barbara Sebők, Petra Merkely, Emese Keszthelyi, Balázs Lintner, Nándor Ács, Attila Keszthelyi, Szabolcs Várbíró, Richárd Tóth et al.
Cancers 2025, 17(6), 921; https://doi.org/10.3390/cancers17060921

Molecular Insights into HR-HPV and HCMV Co-Presence in Cervical Cancer Development
by Rancés Blanco and Juan P. Muñoz
Cancers 2025, 17(4), 582; https://doi.org/10.3390/cancers17040582

Management for Cervical Cancer Patients: A Comparison of the Guidelines from the International Scientific Societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)
by Stefano Restaino, Giulia Pellecchia, Martina Arcieri, Giorgio Bogani, Cristina Taliento, Pantaleo Greco, Lorenza Driul, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani et al.
Cancers 2024, 16(14), 2541; https://doi.org/10.3390/cancers16142541

Impact of PET/CT Imaging with FDG in Locally Advanced Cervical Carcinoma—A Literature Review
by Ottó Molnar, Oreste Mihai Straciuc, Simona Mihuțiu and Liviu Lazăr
Curr. Oncol. 2024, 31(5), 2508-2526; https://doi.org/10.3390/curroncol31050188

The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)
by Daniela Fischerova, Filip Frühauf, Andrea Burgetova, Ingfrid S. Haldorsen, Elena Gatti and David Cibula
Cancers 2024, 16(4), 775; https://doi.org/10.3390/cancers16040775 

Fertility Preservation in Cervical Cancer—Treatment Strategies and Indications
by Lina Salman and Allan Covens
Curr. Oncol. 2024, 31(1), 296-306; https://doi.org/10.3390/curroncol31010019

Cervical Cancer Screening: Current Practices and Future Perspectives
Guest Editor: Dr. Kimon Chatzistamatiou
Submission deadline: 20 March 2026
Clinical Management of Cervical Cancer
Guest Editor: Dr. Vanessa Samouëlian
Submission deadline: 31 March 2026
The Role of Minimally Invasive and Minimally Radical Surgery in Cervical and Endometrial Cancer
Guest Editors: Dr. Raj Naik, Dr. Marie Plante, Dr. Christophe Pomel, Prof. Dr. Roberto Tozzi and Dr. Gwénaël Ferron
Submission deadline: 1 September 2026
Medical Image-Based Cervical Cancer Prevention, Diagnosis, and Treatment
Guest Editors: Dr. Emma R. Allanson and Dr. Ming Yin Lin
Submission deadline: 30 September 2026

 


Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer

Edited by Ranjit Manchanda

https://doi.org/10.3390/books978-3-0365-2983-7

This is a Reprint of the Special Issue Gynaecological Cancers Risk: Breast Cancer, Ovarian Cancer and Endometrial Cancer that was published in Cancers.

9 January 2026
MDPI’s Newly Launched Journals in December 2025


We have expanded our open access portfolio with eight new journals publishing their inaugural issues in December 2025, as well as three journal transfers. These additions span physical sciences, social sciences, arts and humanities, environmental and Earth sciences, medicine and pharmacology, and public health and healthcare. We extend our sincere thanks to the Editors-in-Chief, Associate Editors, and Editorial Board Members who are shaping these journals’ direction. All journals uphold strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

New Journals

Founding Editor-in-Chief(s)

Journal Topics (Selected)

Dr. Elisa Felicitas Arias,

Université PSL, France

Editorial | view inaugural issue

atomic clocks; time and frequency metrology; GNSS systems; relativity and relativistic timekeeping; fundamental physics in space |

view journal scope | submit an article

Prof. Dr. José F.F. Mendes,

University of Aveiro, Portugal

Editorial | view inaugural issue

complex systems; network science; nonlinear dynamics and chaotic behaviour; information theory and complexity; computational complexity |

view journal scope | submit an article

Prof. Dr. Roberto Morandotti,

Institut National de la Recherche Scientifique—Énergie, Matériaux et Télécommunications (INRS), Canada

Editorial | view inaugural issue

light generation; light sources and applications; light control and measurement; human responses to light; lighting design |

view journal scope | submit an article

Prof. Dr. Savvas A. Chatzichristofis,

Neapolis University Pafos, Cyprus

Editorial | view inaugural issue

generative AI and large language models in education; multimodal and embodied AI; personalization and adaptive systems; assessment, feedback, and academic integrity; learning analytics |

view journal scope | submit an article

Prof. Dr. Jon Andoni Duñabeitia,

Universidad Nebrija, Spain

Editorial | view inaugural issue

cognitive psychology; cognitive neuroscience; psycholinguistics; applied linguistics; experimental psychology |

view journal scope | submit an article

Prof. Dr. Caiwu Fu,

Wuhan University, China;

Prof. Dr. Longxi Zhang,

Peking University, China

Editorial | view inaugural issue

cultural practices; cultural theory; cultural policy; cultural heritage; transregional and transnational cultural flows|

view journal scope | submit an article

Dr. Ghassem R. Asrar,

iCREST Environmental Education Foundation, USA

Editorial | view inaugural issue

biosphere interactions, processes, and sustainability; ecosystem science and dynamics; biodiversity conservation; global change and environmental adaptation; biogeochemical cycles |

view journal scope | submit an article

Dr. Giuseppe Mulè,

University of Palermo, Italy

Editorial | view inaugural issue

cardiorenal syndromes; chronic heart failure and chronic kidney disease; cardiorenalmetabolic syndrome; hypertension and diabetes in relation to the abovementioned syndromes; diagnostic techniques |

view journal scope | submit an article

Transferred Journals

Editor-in-Chief

Journal Topics (Selected)

Prof. Dr. Peter Matt,

Lucerne Cantonal Hospital (LUKS), Switzerland

Editorial | view first issue

cardiology; cardiovascular and aortic surgery; cardiovascular anatomy, physiology and pathophysiology; congenital heart disease and pediatric cardiology;

cardiovascular regenerative and reparative medicine |

view journal scope | submit an article

Prof. Dr. Oana Săndulescu,

Carol Davila University of Medicine and Pharmacy, Romania;

National Institute for Infectious Diseases “Prof. Dr. Matei Bals”, Romania

Editorial | view first issue

infectious diseases across clinical and public health domains; epidemiology of communicable diseases; clinical microbiology and applied virology; vaccinology and immunization; host–pathogen interactions and immunity |

view journal scope | submit an article

Dr. Roxana Elena Bohiltea,

“Carol Davila” University of Medicine and Pharmacy, Romania

Editorial | view first issue

public health; disease prevention; screening and early detection; lifestyle interventions and health education; digital and innovative prevention |

view journal scope | submit an article

We would like to thank everyone who has supported the development of open access publishing. If you would like to create more new journals, you are welcome to send an application here, or contact the New Journal Committee (newjournal-committee@mdpi.com).

7 January 2026
Welcoming New Editorial Board Members of Cancers Joined in December 2025

We are pleased to announce that three new scholars have been appointed as Editorial Board Members (EBMs) of Cancers (ISSN: 2072-6694), joining in December 2025. We wish our new member success in both their research and their efforts to develop the journal.

Name: Dr. Sara Piccirillo
Affiliation: Department of Cell Biology and Physiology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA
Interests: glioblastoma; cancer stem-like cells; stem cell & tumor cell biology; cancer genomics

Name: Dr. Bahil Ghanim
Affiliations: 1 Karl Landsteiner University of Health Sciences, Dr. Karl-Dorrek-Straße 30, 3500 Krems, Austria; 2 Department of General and Thoracic Surgery, University Hospital Krems, Mitterweg 10, 3500 Krems, Austria
Interests: thoracic surgery; solitary fibrous tumor; mesothelioma; lung cancer; orphan disease biomarker

Name: Dr. Stergios Boussios
Affiliation: Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London SE1 9RT, UK
Interests: ovarian cancer; homologous recombination of DNA; BRCA genes; PARP inhibitors; cervical cancer; carcinoma of unknown primary; prostate cancer; colorectal cancer; cancer in pregnancy; metastatic spinal cord compression; cancer and autoimmune diseases

Further details about the Editorial Board of Cancers can be found by clicking the following link: https://www.mdpi.com/journal/cancers/editors.

Cancers is recruiting scholars from around the world to join our Editorial Board. To apply for membership, recommend potential candidates, or request further information, please contact the Cancers Editorial Office and provide the following files:

  • A full academic CV;
  • A short cover letter detailing your interest in the position.

31 December 2025
MDPI INSIGHTS: The CEO's Letter #30 - Scaling with Integrity, Highly Cited Researchers, KEMÖ Consortium, Michele Parrinello, and Best PhD Thesis Awards

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts


With colleagues at MDPI headquarters in Basel, representing the people behind our global growth and shared commitment to integrity.

Scaling with Integrity: A Year of Growth, Responsibility, and Trust

When I look back on 2025, one phrase seems to sum up the year: “Scaling with integrity.” That was our watchword for 2025, and it will remain so as we move forward in to 2026.

Our journal portfolio continued to grow in 2025, reflecting the trust of a widening proportion of the scholarly community.

Today, MDPI has 355 journals indexed in Scopus and 330 in Web of Science – a testimonial to the scale at which our journals meet established external quality criteria. During the year, 45 of our journals were newly accepted into Scopus and 29 into Web of Science (this excludes transferred journals to our portfolio that were already indexed), following rigorous, independent evaluation by the world’s leading indexing bodies

Meeting external quality benchmarks

These results underline the fact that scaling responsibly is not only about expanding our catalogue, but also about meeting external quality benchmarks consistently, transparently, and at scale. Our indexing performance remains one of the strongest independent validations of MDPI’s commitment to rigor, trust, and long-term sustainability.

Over the course of 2025, we made targeted investments to ensure that the integrity of our editorial process scaled to keep pace with our growth. We strengthened our editorial governance by doubling down on our dedicated Publication Ethics department, appointing a Head of Ethics, and expanding our research integrity team by the addition of new specialists plus the creation of embedded editorial ethics roles across key journals. We also introduced new internal ethics guidelines, pre-review integrity checks, and monitoring dashboards to help teams identify potential issues and apply consistent standards across our portfolio.

Besides investing in systems and tools, we of course also invested heavily in our people and culture, delivering organisation-wide training on topics such as image integrity, AI use in publishing, and ethical oversight, while actively engaging with the wider publishing community through COPE and STM forums.

All these efforts reflect a simple principle: growth only matters if it is matched by rigor, responsibility, and trust.

Technology and AI: Supporting the editorial decision-making process

At MDPI, AI is designed to assist, not replace, editorial decision-making. It is one element in a broader system that combines people, technology, and processes to support scale responsibly.

In 2025, we continued to invest heavily in technology that supports quality rather than shortcuts. Our AI team doubled in size, ensuring that increased automation goes hand-in-hand with expertise and oversight. Proprietary AI tools such as Scholar Finder have significantly improved the precision of reviewer matching, while Ethicality has been widely adopted across editorial workflows to identify contextual signals, such as scope alignment and citation behaviour, so that human judgment can be applied where it matters most.

Partnerships: Institutional Open Access Program (IOAP) agreements and Societies

Our recent growth is also reflected in the strength of our partnerships. In 2025, we entered into more than 150 new IOAP agreements, bringing our total to 975 active agreements worldwide. This activity included the signing of our first-ever consortium agreements in North America, renewals of all major national consortia in the UK, Switzerland, Sweden, Norway, Austria, and Croatia, and the conclusion of several flat-fee agreements. At the same time, we concluded a total of 30 agreements, encompassing 24 new Society affiliations, four strategic publishing partnerships, and two journal acquisitions.

In 2025, we opened MDPI USA in Philadelphia – our latest global office, which complements our Toronto office in representing North America. MDPI USA is responsible for accelerating Open Access in the US through ongoing support of our scholars and for expanding our institutional and society partnerships.

On the other side of the globe, meanwhile, we signed an IOAP agreement in India, allowing researchers discounted Article Processing Charges (APCs), streamlined APC management for universities, and visibility into submissions, supporting India’s push for wider Open Access by offering flexible models and helping institutions meet national mandates such as Plan S.

Sustainability, sponsorships and awards

We continued to expand our sustainability efforts during 2025, hosting the 11th World Sustainability Forum, awarding CHF 125,000 in sustainability-related funding, and launching the Z-Forum on Sustainability and Innovation conference, which will officially take place in January 2026.

We also saw a record year for conference sponsorships and awards (while establishing new awards such as the Michele Parrinello Award), recognising scholars across disciplines and reinforcing our commitment to supporting the global research community at every stage of the academic journey.

Deepening our relationships

In 2025, I had the opportunity to travel more widely than ever before on MDPI business, meeting many of our stakeholders face to face and relishing the opportunity to gain a deeper understanding of their science communication needs. It was also excellent to visit a large number of MDPI offices and witness the commitment and service orientation of so many of our colleagues around the world. I shall resume my itinerary in the new year, and I look forward to many more such interactions.

Looking ahead to 2026, we will be celebrating a very significant milestone: 30 years of MDPI. From our foundation as a single Open Access journal in 1996 to the global publishing organisation we are today, our mission has remained consistent: advancing Open Access through rigorous and trustworthy scientific communication.

I would like to take this opportunity to thank all our stakeholders – authors, Editors-in-Chief, Editorial Board members, and reviewers – who have placed their trust in us during 2025. On behalf of the entire MDPI team, I look forward to deepening our relationships yet further in 2026 and celebrating 30 Years of Open Science at MDPI, something we’ve built together.


Basel, Switzerland, where MDPI was founded in 1996.

Impactful Research

621 MDPI Editors Named Highly Cited Researchers in 2025

I am pleased to share an important milestone for our editorial community and for MDPI. In late November, Clarivate announced the 2025 Highly Cited Researchers, and 621 MDPI Editorial Board Members were included among the most influential scientific contributors over the past decade! 

The 621 editors come from 33 countries, representing 21 scientific disciplines, and account for nearly one in every ten Highly Cited Researchers globally. This recognition speaks to the depth of expertise across our Editorial Boards and the strength of the scientific communities that choose to collaborate with MDPI. It is important to note that while citation metrics are not in themselves a proxy for quality, they do offer one lens on sustained scientific influence.

“Our strength comes from the scientific communities who choose to work with us”

Why this is important

Having more than 600 editors recognized on this list highlights:

  • The high level of expertise guiding peer review across our journals
  • The global and disciplinary diversity within our Editorial Boards
  • Our commitment to maintaining strong, knowledgeable, and engaged editorial oversight

Impactful science is of course shaped by broad, diverse research communities, and no single metric captures the full picture of research quality. However, this recognition does serve as meaningful, independent affirmation of the calibre of many editors who contribute to MDPI’s work.

A closer look at the recognition

Clarivate’s methodology highlights researchers whose publications rank in the top one per cent by citation count, reflecting consistent influence over the past decade. The process includes:

  • Evaluation of c. 200,000 highly cited papers
  • Removal of retracted publications
  • Filtering of papers with unusually large authorship groups to focus on clear contributions

That so many of our editors meet these thresholds reflects the impact of the communities behind our journals.

What this means going forward

This recognition underlines the fact that our strength comes from the scientific communities who choose to work with us.

For authors, partners, and readers, it confirms that:

  • MDPI journals benefit from editorial guidance grounded in active, high-impact research
  • Our Editorial boards include leaders who are helping shape the future direction of their fields
  • MDPI continues to attract experts who value openness, efficiency, and scientific integrity

For our internal teams, it is a reminder that the work we do every day (supporting editors, refining workflows, and improving systems) directly contributes to the trust placed in MDPI by researchers worldwide.

Thank you to all our editorial teams, publishing staff, and journal relationship specialists, and to everyone who collaborates with our Editorial Boards. Achievements like this are only possible because of your ongoing hard work, dedication, and collaboration.


From our first annual MDPI UK Summit in Manchester, bringing together over 30 Chief Editors and Editorial Board Members to discuss MDPI’s mission, achievements, and collaborations in the UK.

Inside MDPI

MDPI Launches the Michele Parrinello Award for Computational Physical Science

In case you missed it, in November, we announced the launch of the Michele Parrinello Award. This new biennial international award will recognize pioneering contributions in computational physical science. The award honours Michele Parrinello, one of the most influential scientists of the past half-century in atomistic simulations and computational materials research.

This award reflects MDPI’s long-standing commitment to recognizing scientific excellence, supporting foundational research, and inspiring the next generation of scholars across disciplines.

“Be confident that what you do is meaningful”

Honouring a transformative scientific legacy

Professor Parrinello’s work has fundamentally reshaped how scientists model matter at the atomic scale. Together with Roberto Car, he introduced ab initio molecular dynamics, widely known as the Car–Parrinello method, opening new pathways in electronic structure calculations and molecular simulations. His subsequent contributions, including the Parrinello–Rahman method and metadynamics, have become core tools across physics, chemistry, materials science, and increasingly biology.

“Do not be afraid of new things. I see it many times when we discuss a new thing that young people are scared to go against the mainstream a little bit, thinking, ‘What is going to happen to me?’ and so on. Be confident that what you do is meaningful, and do not be afraid, do not listen too much to what other people have to say.”

 – Professor Michele Parrinello

A global, community-led award

The award committee is chaired by Xin-Gao Gong, Professor of Physics at Fudan University and academician of the Chinese Academy of Sciences.

The Institute for Computational Physical Sciences at Fudan University will serve as the supporting institute, reinforcing the award’s international and cross-cultural foundation.

Nominations for the first edition of the Michele Parrinello Award opened on 1 November 2025, with submissions accepted until March 2026. The award will recognize scientists whose work has advanced computational physical science across physics, chemistry, and materials research – fields increasingly central to energy, sustainability, advanced manufacturing, and technological innovation.

Why this matters for MDPI

The Michele Parrinello Award is part of the MDPI Sustainability Foundation, which supports science as a driver of long-term societal progress.

Alongside other foundation-level honours, including the World Sustainability Award, the Emerging Sustainability Leader Award, and the Tu Youyou Award, this new prize builds on our role in supporting excellence across career stages and disciplines.

MDPI journals and programs continue to recognize researchers through Best Paper Awards, Young Investigator Awards, Travel Awards, Best PhD Thesis Awards, and Outstanding Reviewer Awards. Together, these initiatives reflect a simple belief: strong scientific communities are built through recognition, trust, and sustained support.

As MDPI approaches its 30th anniversary, the launch of the Michele Parrinello Award highlights our commitment not only to publishing research but also to helping shape the future of science by celebrating those who expand its boundaries.

Coming Together for Science

KEMÖ Consortium (Austria) Extends Open Access Agreement with MDPI until 2027

I’m pleased to share that MDPI has renewed its Institutional Open Access Program (IOAP) agreement with the Austrian library consortium KEMÖ, extending our partnership through 2027.

The renewed agreement now includes 23 Austrian institutions, with the Medical University of Vienna and the University of Natural Resources and Life Sciences (BOKU) joining the partnership. Participating institutions benefit from APC discounts across MDPI’s more than 495 journals, with centralized funding options further reducing the administrative burden for researchers and libraries.

“This renewal reflects shared commitment to advancing Open Access publishing in Europe”

Austria continues to be an important and engaged research community for MDPI, with 525+ Austrian Editorial Board Members, eight Editors-in-Chief, and 15 Section Editors-in-Chief contributing to our journals.

This renewal reflects long-term trust and shared commitment to advancing Open Access publishing in Europe, and improves MDPI’s collaboration with national OA infrastructures such as the Open Access Monitor Austria. Such long-term agreements show how MDPI’s growth is increasingly built on institutional trust, collaboration, and shared commitment to Open Access.

A big thank-you to the IOAP team and everyone involved in supporting this partnership.

Closing Thoughts

Celebrating the Next Generation of Scholars: MDPI’s 2024 Best PhD Thesis Awards

One of the privileges of working in scholarly publishing is supporting the beginning of new scientific journeys. We recently announced the recipients of MDPI’s 2024 Best PhD Thesis Awards, recognizing some of the most promising emerging researchers across disciplines.

These awards do more than celebrate academic excellence. They reflect something deeper about our mission: supporting the next generation of authors and the future of Open Science.

Recognition of Excellence

This year, we made awards to 55 early-career researchers across seven fields:

For those of you who have completed a PhD, you’ll know first-hand that behind each number is a story of perseverance, curiosity, and sustained effort. These researchers represent institutions around the world, with thesis topics spanning:

  • Brain–machine interfaces and neural engineering
  • Sustainable materials and next-generation batteries
  • Cancer genomics, tumour microenvironments, and immunotherapy
  • AI-driven image analysis, robotics, and computational models
  • Climate change monitoring and environmental risk assessment
  • Regenerative medicine, biomaterials, and drug development

These dissertations are early signs of the scientific directions that will shape the coming decade.

“Our mission is about building a global community of authors”

Why this is important

Every year, millions of scholars begin their research careers with limited visibility and few platforms for sharing their work. By recognizing outstanding PhD theses, we elevate authors early in their academic journeys, build MDPI’s connection to the global research community, reinforce our commitment to quality and rigor, and highlight the depth and breadth of scholarship published across our portfolio (from biology to materials science to mathematics).

A foretaste of the future

These 55 awardees represent the next generation of researchers whose work will influence science, policy, and society in the years ahead. What we support today helps shape the scientific ecosystem of tomorrow. Our mission goes beyond publishing papers. It is about building a global community of authors who will define the next era of scientific discovery.

To explore more about MDPI Awards, including current and upcoming Best PhD Thesis Awards, please click here.

Thank you to the editors, reviewers, and teams across MDPI who make these awards possible each year.

Everything we achieved this year was made possible by the collective effort of our global teams and the trust placed in us by the scholarly community. Thank you again, and here’s to the successful continuation of our collaboration in 2026!

Stefan Tochev
Chief Executive Officer
MDPI AG

30 December 2025
Cancers | Issue Cover Articles Published in 2025

The articles below have been selected as 2025 issue cover articles by the Editorial Office of Cancers (ISSN: 2072-6694). These articles came from multiple fields within the scope of Cancers, and we hope they can provide insights and references for scholars in related fields.

  1. Components of the Endosome-Lysosome Vesicular Machinery as Drivers of the Metastatic Cascade in Prostate Cancer
    by Bukuru Dieu-Donne Nturubika, Jessica Logan, Ian R. D. Johnson, Courtney Moore, Ka Lok Li, Jingying Tang, Giang Lam, Emma Parkinson-Lawrence, Desmond B. Williams, James Chakiris et al.
    Cancers 2025, 17(1), 43; https://doi.org/10.3390/cancers17010043

  1. Venous Thromboembolism in Patients with Neuroendocrine Neoplasms: A Systematic Review of Incidence, Types, and Clinical Outcomes
    by Sara Massironi, Lorenzo Gervaso, Fabrizio Fanizzi, Paoletta Preatoni, Giuseppe Dell’Anna, Nicola Fazio and Silvio Danese
    Cancers 2025, 17(2), 212; https://doi.org/10.3390/cancers17020212

  1. An Assessment of Young Adults’ Awareness and Knowledge Related to the Human Papillomavirus (HPV), Oropharyngeal Cancer, and the HPV Vaccine
    by Eric N. Davis and Philip C. Doyle
    Cancers 2025, 17(3), 344; https://doi.org/10.3390/cancers17030344

  1. Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma
    by Alisha Kashyap, Julia Dai and Xiao Ni
    Cancers 2025, 17(4), 568; https://doi.org/10.3390/cancers17040568

  1. AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers
    by Axel Gschwind and Stephan Ossowski
    Cancers 2025, 17(5), 714; https://doi.org/10.3390/cancers17050714

  1. Immunological Network Signature of Naïve Non-Oncogene-Addicted Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Therapy: A Pilot Study
    by Pasquale Sibilio, Ilaria Grazia Zizzari, Alain Gelibter, Marco Siringo, Lucrezia Tuosto, Angelica Pace, Angela Asquino, Flavio Valentino, Arianna Sabatini, Manuela Petti et al.
    Cancers 2025, 17(6), 922; https://doi.org/10.3390/cancers17060922

  1. From Diagnosis to Survivorship: The Role of Social Determinants in Cancer Care
    by Abiha Abdullah, Zeyu Liu and Michele Molinari
    Cancers 2025, 17(7), 1067; https://doi.org/10.3390/cancers17071067

  1. Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients
    by Srushti Borkar, Fenja Markus, Agnes Oetting, Stefanie Schmidt, Christine Vössing, David Horst, Markus Möbs, Elena I. Braicu, Frank Griesinger, Katja Horling et al.
    Cancers 2025, 17(8), 1266; https://doi.org/10.3390/cancers17081266

  1. Understanding the Impact of Deep Learning Model Parameters on Breast Cancer Histopathological Classification Using ANOVA
    by Nerea Hernandez, Francisco Carrillo-Perez, Francisco M. Ortuño, Ignacio Rojas and Olga Valenzuela
    Cancers 2025, 17(9), 1425; https://doi.org/10.3390/cancers17091425

  1. Long Non-Coding RNAs and RNA-Binding Proteins in Pancreatic Cancer Development and Progression
    by Pit Preckwinkel, Khursheed Ul Islam Mir, Florian W. Otto, Hend Elrewany, Andrea Sinz, Stefan Hüttelmaier, Nadine Bley and Tony Gutschner
    Cancers 2025, 17(10), 1601; https://doi.org/10.3390/cancers17101601

  1. Protein Biomarkers Enable Sensitive and Specific Cervical Intraepithelial Neoplasia (CIN) II/III+ Detection: One Step Closer to Universal Cervical Cancer Screening
    by Samrin F. Habbani, Sayeh Dowlatshahi, Nathanael Lichti, Meaghan Broman, Lucy Tecle, Scott Bolton, Lisa Flowers, Rafael Guerrero-Preston, Jacqueline C. Linnes and Sulma I. Mohammed
    Cancers 2025, 17(11), 1763; https://doi.org/10.3390/cancers17111763

  1. New Approaches in Radiotherapy
    by Matthew Webster, Alexander Podgorsak, Fiona Li, Yuwei Zhou, Hyunuk Jung, Jihyung Yoon, Olga Dona Lemus and Dandan Zheng
    Cancers 2025, 17(12), 1980; https://doi.org/10.3390/cancers17121980

  1. Role of Vascular Liver Diseases in Hepatocellular Carcinoma Development
    by Lucia Giuli, Valeria De Gaetano, Giulia Venturini, Ersilia Arvonio, Marco Murgiano, Antonio Gasbarrini, Francesco Santopaolo and Francesca Romana Ponziani
    Cancers 2025, 17(13), 2060; https://doi.org/10.3390/cancers17132060

  1. Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation
    by Madhavi Nayyar, Ricardo C. B. de Menezes, Sikander Ailawadhi and Ricardo D. Parrondo
    Cancers 2025, 17(14), 2298; https://doi.org/10.3390/cancers17142298

  1. Supercharged Natural Killer (sNK) Cells Inhibit Melanoma Tumor Progression and Restore Endogenous NK Cell Function in Humanized BLT Mice
    by Kawaljit Kaur, Paytsar Topchyan and Anahid Jewett
    Cancers 2025, 17(15), 2430; https://doi.org/10.3390/cancers17152430

  1. Risk Stratification of Thyroid Nodules Using Ultrasound Cine-Loop Video Sequences
    by Tabea Nikola Schmidt, Martin Freesmeyer, Christian Kühnel, Falk Gühne, Larissa Rosenbaum, Robert Drescher and Philipp Seifert
    Cancers 2025, 17(16), 2616; https://doi.org/10.3390/cancers17162616

  1. Workflow Efficiency in Vaginal Cuff High Dose Rate Brachytherapy Using Artificial Intelligence-Based Organ Segmentation and Multi-Channel Cylinder Modeling
    by Yohan A. Walter, Lane Rosen, Olivia Moncrief, Bethany Broekhoven, Troy Jacobs, Joseph Syh, Joseph Dugas, Kelsi Hoffnung, Mitchell Wolden, Heidi Wimberly et al.
    Cancers 2025, 17(17), 2751; https://doi.org/10.3390/cancers17172751

  1. Revealing the Angiogenic Signature of FH-Deficient Breast Cancer: Genomic Profiling and Clinical Implications
    by Liat Anabel Sinberger, Noa Keren-Khadmy, Assaf Goldberg, Tamar Peretz-Yablonski, Amir Sonnenblick and Mali Salmon-Divon
    Cancers 2025, 17(18), 2942; https://doi.org/10.3390/cancers17182942

  1. Spatial Transcriptomics Reveals Distinct Architectures but Shared Vulnerabilities in Primary and Metastatic Liver Tumors
    by Swamy R. Adapa, Sahanama Porshe, Divya Priyanka Talada, Timothy M. Nywening, Mattew L. Anderson, Timothy I. Shaw and Rays H. Y. Jiang
    Cancers 2025, 17(19), 3210; https://doi.org/10.3390/cancers17193210

  1. The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies
    by Ali Iftikhar, Niaz Mahmood and Shafaat A. Rabbani
    Cancers 2025, 17(20), 3309; https://doi.org/10.3390/cancers17203309

  1. Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms
    by Alessandro Costa and Massimo Breccia
    Cancers 2025, 17(21), 3397; https://doi.org/10.3390/cancers17213397

  1. Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
    by Ayaka Ohiwa, Tadashi Nishimura, Tadashi Sakaguchi, Hajime Fujimoto, Shuji Kodama, Atsushi Fujiwara, Hiroki Nakahara, Taichi Isobe, Takaya Hirai, Akihiko Yagi et al.
    Cancers 2025, 17(22), 3630; https://doi.org/10.3390/cancers17223630

  1. SBFI Inhibitors Reprogram Transcriptomic Landscape of Prostate Cancer Cells Leading to Cell Death
    by Shubhra Rajput, Joseph F. LaComb, Chris Gordon, Hehe Wang, Manisha Sarder, Martin Kaczocha, Iwao Ojima and Agnieszka B. Bialkowska
    Cancers 2025, 17(23), 3723; https://doi.org/10.3390/cancers17233723

  1. The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia
    by Alejandro Segura Tudela, Ron Geller, Bruno Paiva, Sara Carmen Torres Sánchez, Elisa González Romero, Pilar Lloret Madrid, Pedro Chorão, Javier de la Rubia, Pau Montesinos and Manuel Guerreiro
    Cancers 2025, 17(24), 3892; https://doi.org/10.3390/cancers17243892

30 December 2025
Cancers | Title Story Articles from the Second Half of 2025


We are delighted to present a list of title story articles selected to feature at the top of the Cancers (ISSN: 2072-6694) homepage for the second half of 2025. These articles cover a wide range of topics, including cancer genomics, whole-genome sequencing, cancer diagnosis and therapy, cancer metastasis, liquid biopsy, precision oncology and quality of life. We hope you find these publications to be of particular interest.

1. The Concept of “Platinum Sensitivity” in Endometrial Cancer
by Shoji Nagao, Atsushi Fujikawa, Ryoko Imatani, Yoshinori Tani, Hirofumi Matsuoka, Naoyuki Ida, Junko Haraga, Chikako Ogawa, Keiichiro Nakamura and Hisashi Masuyama
Cancers 2025, 17(15), 2557; https://doi.org/10.3390/cancers17152557

2. L1CAM Reliably Distinguishes Low-Grade Oncocytic Tumor from Other Eosinophilic Renal Neoplasms: A Multicenter Immunohistochemical Study with Diagnostic Implications
by Luciana Scuccimarri, Antonio d’Amati, Francesco Pierconti, Angela Santoro, Luigia Ciampi, Tiziana Montrone, Francesco Alfredo Zito, Giuseppe Lucarelli, Guido Rindi, Gian Franco Zannoni et al.
Cancers 2025, 17(15), 2440; https://doi.org/10.3390/cancers17152440

3. Scaling for African Inclusion in High-Throughput Whole Cancer Genome Bioinformatic Workflows
by Jue Jiang, Georgina Samaha, Cali E. Willet, Tracy Chew, Vanessa M. Hayes and Weerachai Jaratlerdsiri
Cancers 2025, 17(15), 2481; https://doi.org/10.3390/cancers17152481

4. Comprehensive Longitudinal Linear Mixed Modeling of CTCs Illuminates the Role of Trop2, EpCAM, and CD45 in CTC Clustering and Metastasis
by Seth D. Merkley, Huining Kang, Ursa Brown-Glaberman and Dario Marchetti
Cancers 2025, 17(16), 2717; https://doi.org/10.3390/cancers17162717

5. Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast Cancer
by Sarah Childs, Ryoko Semba, Lucy Haggstrom and Elgene Lim
Cancers 2025, 17(19), 3174; https://doi.org/10.3390/cancers17193174

6. Dermal Mitoses Correlate with Surgical Burden in Lentigo Maligna Melanoma: PRAME for Margin Assessment
by Thomas Leibing, Clara Ziemann, Cyrill Géraud, Jochen Utikal and Sebastian A. Wohlfeil
Cancers 2025, 17(19), 3112; https://doi.org/10.3390/cancers17193112

7. The Tumor Environment in Peritoneal Carcinomatosis and Malignant Pleural Effusions: Implications for Therapy
by Paige O. Mirsky, Patrick L. Wagner, Maja Mandic-Popov, Vera S. Donnenberg and Albert D. Donnenberg
Cancers 2025, 17(19), 3217; https://doi.org/10.3390/cancers17193217

26 December 2025
Cancers | Highly Viewed Special Issues on Cancer Pathophysiology


We are delighted to share some highly viewed Special Issues on cancer pathophysiology in Cancers (ISSN: 2072-6694). Some of them are still open for submission. The following is a list of the Special Issues that we believe will interest you.

Special Issues

The Role of Sphingolipids in Cancer Progression
Guest Editor: Dr. Jeremy Hengst
Submission deadline: 30 October 2026

The Molecular Biology of Cholangiocarcinoma
Guest Editors: Prof. Dr. Kevin Gaston and Prof. Dr. Padma-Sheela Jayaraman
Submission deadline: 31 July 2026

Tumor Suppressor Genes and Oncogenes: Genome-Wide Insights into Cancer Biology
Guest Editor: Dr. Meena Kanduri
Submission deadline: 31 December 2026

Clinical Pathology in Cancer: From Diagnosis to Precision Medicine
Guest Editor: Prof. Dr. Georgia Levidou
Submission deadline: 28 March 2026

Metabolism and Precision Oncology
Guest Editors: Dr. Rays H.Y. Jiang and Prof. Dr. Gloria C. Ferreira
Submission deadline: 31 October 2026

Insulin Resistance, Diabetes, and Cancer: An Overview of the Pathogenetic Mechanisms
Guest Editors: Dr. Kumar Ganesan and Prof. Dr. Kunka Mohanram Ramkumar
Submission deadline: 31 May 2026

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

25 December 2025
Cancers | Highly Viewed Special Issues on Clinical Research of Cancer


We are delighted to share some highly viewed Special Issues on clinical research of cancer in Cancers (ISSN: 2072-6694). Some of them are still open for submission. The following is a list of the Special Issues that we believe will interest you.

Special Issues

Advances in Clinical Trials and Precision Medicine for Neuro-Oncology
Guest Editor: Dr. Malaka Ameratunga
Submission deadline: 30 September 2026

Advances in Clinical Trials: Outcome, Innovations, Challenges, and Ethical Practice in Cancer Research 2025–2026
Guest Editors: Prof. Dr. Naoto T. Ueno and Prof. Dr. David R. Gandara
Submission deadline: 30 June 2026

The Clinical Trials and Management of Acute Myeloid Leukemia: 2nd Edition
Guest Editor: Dr. Margaret T. Kasner
Submission deadline: 7 August 2026

Acute Myeloid Leukemia: Novel Therapeutic Agents and Clinical Trials
Guest Editor: Prof. Dr. Wieslaw W. Jedrzejczak
Submission deadline: 30 November 2026

Clinical Trials and Translational Research in Multiple Myeloma
Guest Editor: Dr. Laszlo Varoczy
Submission deadline: 30 September 2026

Cancer Drug Resistance: Mechanisms and Overcoming Strategies
Guest Editor: Dr. Jessica M. Konen
Submission deadline: 30 September 2026

You are invited to view and submit relevant papers to the journal Cancers at the following link:
https://www.mdpi.com/journal/cancers.

Cancers Editorial Office

25 December 2025
Interview with Dr. Sergio Marco Salas—Winner of the Best Oral Presentation Award


In November 2025, the journal Cancers (ISSN: 2072-6694) successfully hosted its first in-person conference, “CancersScape: Spatial Biology of the Tumor Ecosystem”, in Barcelona, Spain (5–7 November 2025). The event brought together leading global experts to discuss cutting-edge advances in multi-omics and spatial biology aimed at decoding the tumor microenvironment.

We are honored to congratulate Dr. Sergio Marco Salas on receiving one of the conference’s Best Oral Presentation Awards, in recognition of his outstanding contribution.

Brief introduction:
Dr. Sergio Marco Salas is a postdoctoral researcher at Helmholtz Munich, where he conducts his work under the supervision of Prof. Fabian Theis. He holds a multidisciplinary background spanning computational biology, spatial transcriptomics, and image-based omics technologies. His current research is dedicated to advancing the analytical framework of spatial omics by developing novel computational tools and methodologies for the scientific community. Through this work, he aims to improve the interpretation of complex spatially resolved molecular data and to uncover previously inaccessible layers of biological organization.

In the following interview, Dr. Salas shares the story behind his award-winning research—from its initial inspiration and key findings to his vision for the future of spatial biology—and offers valuable advice for the next generation of oncology scientists.

1. Could you please briefly introduce the main content of the award-winning paper?
In our recent study, we investigated a largely overlooked component of spatial transcriptomics data: RNA signals that cannot be assigned to segmented cells, which we refer to as unassigned RNA (uRNA). We systematically characterize the nature of these signals and quantify the contribution of technical factors, such as segmentation inaccuracies and molecular diffusion. Importantly, we demonstrate that not all unassigned RNA has a purely technical origin. By comparing multiple spatial transcriptomics technologies applied to the same tissue types, we observe a high degree of consistency in uRNA profiles. Our results suggest that biological phenomena, including intracellular RNA organization and cellular protrusions, play a significant role in shaping these signals. In addition, we have developed an analytical package, called troutpy, to enable the community to systematically explore these signals.

2. What initially inspired your research interest in this field?
Spatial omics technologies, and spatial transcriptomics in particular, generate exceptionally complex datasets. While the field has expanded rapidly in recent years, with hundreds of studies now published annually, our understanding of the full analytical and biological potential of measuring individual molecules at subcellular resolution remains incomplete. This gap between technological capability and biological interpretation has been a strong motivating factor for me. I am driven by the challenge of helping to decipher the underlying principles of spatial biology and to translate these measurements into meaningful biological insight.

3. What are the future research frontiers in this field?
Despite the remarkable progress achieved so far, spatial transcriptomics remains a rapidly evolving field with substantial room for development. Beyond its growing diagnostic and prognostic impact in oncology, analytical limitations still constrain the scope of biological questions that can be addressed. Future directions include the integration of true multimodal spatial assays, ideally extending into three dimensions and incorporating temporal information. In parallel, there is a clear need to address the high cost of current technologies. Developing more accessible and cost-effective platforms will be essential for the widespread adoption of spatial omics in both research and clinical settings.

4. What advice would you give to early-career researchers aiming to make an impact in oncology?
My advice to early-career researchers is to remain attentive to emerging technologies and methodological innovations. While the repertoire of established experimental and analytical approaches is extensive, many critical questions in oncology remain difficult to answer due to technical limitations. The development and thoughtful application of new technologies, combined with rigorous experimental design, will be key to overcoming these barriers. Such an approach will not only accelerate discovery but also create meaningful opportunities for impactful contributions to the field.

Back to TopTop